acd679

ACD679 is a small molecule drug candidate developed by AlzeCure Pharma as part of their Alzstatin platform for the treatment of Alzheimer's disease. It acts as a gamma-secretase modulator (GSM), reducing the production of toxic amyloid beta 42 (Aβ42) in the brain, which is believed to play a key pathogenic role in Alzheimer's disease. By modulating gamma-secretase activity, ACD679 not only decreases levels of Aβ42 but also increases shorter, non-aggregating forms such as Aβ37 and Aβ38, which may further restrict harmful plaque formation. The compound is designed for oral administration and demonstrates good blood-brain barrier penetration. As of early 2024, ACD679 remains in preclinical development[1][2][5][6].